Rule 3.19A.2

# **Appendix 3Y**

## **Change of Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity:	Life360, Inc.
ARBN:	629 412 942

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	James Synge
Date of last notice	16 June 2022

#### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct	
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	-	
Date of change	20 May 2022	
No. of securities held prior to change	<ul> <li>1,441,041 Chess Depositary Interests (CDIs)</li> <li>16,887 Shares of Common Stock (Shares)(equivalent to 50,661 CDIs)</li> <li>193,137 CDIs held by ICCA Labs, LLC¹</li> <li>211,720 CDIs held by Stynge Pty Ltd ATF Sandy Bay Trust.</li> <li>4,581 Restricted Stock Units (RSUs)</li> <li>27,997 Options over Shares (Options)</li> </ul>	

<sup>&</sup>lt;sup>1</sup> James Synge is a member of ICCA Labs, LLC, an entity that holds Life360 CDIs. The number of CDIs attributable to James Synge by reason of his membership interest in ICCA Labs, LLC is 193,137.

<sup>+</sup> See chapter 19 for defined terms.

Class	Options	
Number acquired	5,975 Options	
Number disposed	-	
Value/Consideration  Note: If consideration is non-cash, provide details and estimated valuation	Options are granted for no consideration. Each option has an exercise price of US\$8.19. Options have been granted in lieu of the payment of Director and Committee fees. <sup>2</sup>	
No. of securities held after change	<ul> <li>1,441,041 CDIs</li> <li>16,887 Shares (equivalent to 50,661 CDIs)</li> <li>193,137 CDIs held by ICCA Labs, LLC</li> <li>211,720 CDIs held by Stynge Pty Ltd ATF Sandy Bay Trust.</li> <li>4,581 RSUs</li> <li>33,972 Options</li> </ul>	
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of additional options approved by shareholders at the 2022 AGM following a calculation error which understated the number of options granted (and notified) by 5,975 options.	

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A

 $<sup>^2</sup>$  This Appendix 3Y updates the Appendix 3Y lodged with the ASX on 27 May 2022 whereby:

Appendix 3Y Page 2 01/01/2011

<sup>• 4,581</sup> RSUs were granted in lieu of the payment of US\$37,500 of Director and Committee Fees.

 <sup>21,769</sup> Options (being the 15,794 options set out in the Appendix 3Y lodged on 27 May 2022 together
with the 5,975 options the subject of this Appendix 3Y) RSUs were granted in lieu of the payment of
US\$87,500 of Director and Committee Fees.

<sup>+</sup> See chapter 19 for defined terms.

No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration  Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

## Part 3 – \*Closed period

Were the interests in the securities or contracts detailed above traded during a *closed period where prior written clearance was required?	No.
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

<sup>+</sup> See chapter 19 for defined terms.